Cell-Based Drugmaker Cellarity Nabs $123M From Investors
Cellarity, which develops drugs with a focus on addressing disease at the cellular level as opposed to molecular, said Thursday it has secured $123 million from a group of investors that...To view the full article, register now.
Already a subscriber? Click here to view full article